


10/523444

Rec'd PCT/PTO 31 JAN 2005

PATENT
ATTORNEY DOCKET NO. 50304/059001

Certificate of Mailing	
Date of Deposit: <u>January 31, 2005</u>	Label Number: <u>EV544139466US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
<u>Elvis De La Cruz</u> Printed name of person mailing correspondence	 Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	GILLES et al.	Art Unit:	To Be Assigned
Serial No.:	To Be Assigned	Examiner:	To Be Assigned
Filed:	January 31, 2005	Customer No.:	21559
Title:	ANTI-IDIOTYPIC ANTIBODIES AGAINST FACTOR VIII INHIBITOR AND USES THEREOF		

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. Copies of the International Search Report and the International Preliminary Examination Report issued in a counterpart application are also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed with the application.

If there are any other charges or any credits, please apply them to Deposit Account

No. 03-2095.

Respectfully submitted,

Date: 31 January 2005



James D. DeCamp, Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.		50304/059001	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		(37 CFR §1.98(b))		Serial No.		To Be Assigned	
				Applicant		GILLES et al.	
				Filing Date		January 31, 2005	
				Group		To Be Assigned	
				IDS Filed		January 31, 2005	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)	
	WO 99/58680	11/18/1999	WIPO				
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
	Genbank accession number: AAW27416 corresponding to the International Application WO9710354-A1 (Kyowa Hakko Kogyo KK). 20.03.97.						
	Genbank accession number: AAR52526 corresponding to the European Application EP592106-A1 (Immunogen Inc.) 13.04.94.						
	Genbank accession number: AX417628 corresponding to the International Application WO231510 (PEPSCCAN SYSTEMS BV) 18.06.02.						
	Genbank accession number: AR144014 corresponding to the U.S. Application US6210671 (Protein Design Labs, Inc.) 03-04.01.						
	Genbank accession number: AAT38510 corresponding to the International Application WO9632495-A1 (LG Chem. Ltd.) 06.04.96						
	Gilles et al., "Antibodies to Idiotypes of Human Monoclonal Antifactor VIII (FVIII) Antibodies Neutralise Their Inhibitory Activity," Blood 94 (Suppl. 10, Part 1):460, abstract 2048 (1999)						
	Gilles et al., "Neutralization Antiidiotypic Antibodies to Factor VIII Inhibitors After Desensitization in Patients with Hemophilia A," J. Clin. Invest. 97:1382-1388 (1996)						
	Jacquemin, "Mechanism and Kinetics of Factor VIII Inactivation: Study With an IgG4 Monoclonal Antibody Derived from a Hemophilia A Patient With Inhibitor," Blood 92:496-506 (1998)						
	Lubahn and Reisner, "Characterization of a Monoclonal Anti-Idiotypic Antibody to Human Anti-Factor VIII Antibodies," Proc. Natl. Acad. Sci. USA 87:8232-8236 (1990)						
	Saint-Remy, "Anti-Idiotypic Antibodies: From Regulation to Therapy of Factor VIII Inhibitors," Vox Sang 77 (supp 1):21-24 (1999)						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							